These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32678519)

  • 1. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
    Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
    CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.
    Zhou Y; Wang X; Huang X; Li XD; Cheng K; Yu H; Zhou YJ; Lv P; Jiang XB
    CNS Neurosci Ther; 2020 Mar; 26(3):309-318. PubMed ID: 31710183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
    Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
    Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.
    Xu H; Chai SS; Lv P; Wang JJ
    Medicine (Baltimore); 2021 Nov; 100(46):e27931. PubMed ID: 34797350
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
    Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
    CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
    Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
    CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
    Lvu W; Fei X; Chen C; Zhang B
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
    Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
    Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collagen Type III Alpha 1 chain regulated by GATA-Binding Protein 6 affects Type II IFN response and propanoate metabolism in the recurrence of lower grade glioma.
    Huang R; Li Z; Zhu X; Yan P; Song D; Yin H; Hu P; Lin R; Wu S; Meng T; Zhang J; Huang Z
    J Cell Mol Med; 2020 Sep; 24(18):10803-10815. PubMed ID: 32757451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGS16 promotes glioma progression and serves as a prognostic factor.
    Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
    CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.
    Liu B; Liu Z; Wang Y; Lian X; Han Z; Cheng X; Zhu Y; Liu R; Zhao Y; Gao Y
    Mol Med; 2021 Sep; 27(1):117. PubMed ID: 34556022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated bioinformatics analysis and experimental validation reveal the relationship between ALOX5AP and the prognosis and immune microenvironment in glioma.
    Song P; Deng H; Liu Y; Zhang M
    BMC Med Genomics; 2024 Aug; 17(1):218. PubMed ID: 39169376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches.
    Hu W; Li D; Yang Y; Zheng Y; Zeng J; Sai K
    Int Immunopharmacol; 2024 Sep; 139():112665. PubMed ID: 39002523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.